Drug intelligence / Profile preview

HT-001 (Hoth Therapeutics)

Development stage: Preclinical
Lead developer: Hoth Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

HT-001 is an investigational small molecule dual agonist of the G-protein coupled receptors GPR40 (Free fatty acid receptor 1) and GPR120 (Free fatty acid receptor 4), currently in preclinical development by Halo Therapeutics. Specifically targeted for obesity maintenance therapy, HT-001 aims to prevent weight regain by modulating gut-receptor signaling to the central nervous system (CNS) appetite centers and enhancing incretin pathways. By activating these receptors, the drug is intended to regulate metabolic homeostasis and satiety, providing a pharmacological approach to long-term weight management following initial weight loss.

Other names: Maintenance Therapy

Targets

FFAR4 (Free fatty acid receptor 4)FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on HT-001 (Hoth Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-001 (Hoth Therapeutics).

Explore the full profile